Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Antiretroviral
Indinavir is an HIV protease inhibitor. It acts by binding to the active site of the HIV protease enzyme, preventing the cleavage of viral Gag and Gag-Pol polyproteins. This inhibition results in the formation of immature, non-infectious HIV particles, thereby hindering viral replication.
X
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Increased plasma levels of indinavir (by azoles); increased azole plasma levels (by indinavir).
Source: Harrison 22e · p1742
Increased risk of arrhythmogenic potential.
Exercise caution with coadministration.
Source: KDT 7e
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Significantly increased alprazolam plasma concentrations, leading to enhanced sedative and psychomotor effects.
Avoid concomitant use. If co-administration is unavoidable, reduce alprazolam dose by 50-75% and monitor for increased sedation.
Source: DDInter
Increase amiodarone levels.
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: synergy.
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-13 · House clinical team